Missing Parts of Batch Records Lead to 483 for Drugmaker

Incomplete batch records and poor testing of finished drugs resulted in a Form 483 for Cerovene. During an October inspection of the company’s Valley Cottage, N.Y., facility, investigators found that Cerovene’s batch records for drug-coated capsules didn’t include the in-process testing for identity, purity and quality.
Drug GMP Report